55: Procedure/treatment/drug is deemed experimental/investigational by the payer.
The payer classifies this service, treatment, or drug as experimental or investigational under its medical policy, meaning it falls outside what the plan considers proven, standard care.
What the group code means
- PR
- Patient Responsibility. The amount may be billed to the patient.
Why it fires
- The payer's medical policy specifically lists this treatment or drug as experimental or investigational
- The service lacks FDA approval for this indication, or lacks sufficient peer-reviewed evidence per the payer's technology assessment
- Off-label drug use was billed without payer-required supporting compendia citations
Corrective actions, ranked
- 1
Review the payer's medical policy
Read the specific policy citation used to classify the treatment as experimental to understand what evidence standard is required.
- 2
Gather clinical evidence
Compile peer-reviewed literature, compendia listings, or FDA approval documentation that may counter the experimental classification.
- 3
Consider an external review
Many states allow an independent external review for experimental or investigational denials if the internal appeal is unsuccessful.
Is it worth appealing
Appeal is often worthwhile when strong clinical literature or an FDA-approved indication supports the treatment. These denials are commonly overturned on external review when evidence is compelling.
Retrieved 2026-07-18.
Do not let this happen again
Scrub the claim against NCCI PTP and MUE edits before you submit, free and in your browser.
DenialPath provides billing and administrative guidance based on published CMS and X12 sources. It is not medical advice, not a coverage determination, and not a guarantee of payment. NCCI and MUE edits are republished quarterly and payer policies vary by contract. Always confirm against the payer's own current policy before submitting or appealing.